Skip to main content
Premium Trial:

Request an Annual Quote

Rheonix Receives SBIR Grant to Finish Development of HIV Assay

NEW YORK (GenomeWeb) – Rheonix announced today that it has received a $1.5 million Small Business Innovation Research Phase II grant from the National Institutes of Health to continue development of its fully automated self-confirming assay for the simultaneous detection of HIV/AIDS antibodies and viral RNA in a single specimen.

The system is designed to simplify HIV testing and eliminate the need for multiple visits by a patient to healthcare providers.

Under a now-completed SBIR Phase I grant, the company developed a proof-of-concept test based on its automated Rheonix Chemistry and Reagent Device platform, which performs sample extraction, purification, amplification, and detection.

The company said that the Phase II grant, which runs for 18 months, will be used to develop a commercial-ready test that will be deployed in the developing world.

The Scan

Less Than Half

An effort to reproduce key findings from high-profile preclinical cancer studies finds less than half could be replicated, according to the Scientist.

Still Some SARS-CoV-2 Sequencing Holes

The Wall Street Journal reports that viral genomic surveillance has improved in the US, though says there are still gaps.

Avoiding Passing Them On

People with known disease-linked genetic variants are turning to in vitro fertilization so as to not pass those variants to their children, the Washington Post says.

PNAS Papers on Long Cell-Free DNA in Maternal Plasma, Genetic Propensity for Voting

In PNAS this week: long, cell-free DNA of maternal and fetal origins identified in maternal plasma, and more.